

Contents

Description	Page No.
List of Figures	xv
List of Tables	xviii
List of Abbreviations & Symbols	xix
Preface	xx
Graphical Abstract	xxiv
Chapter 1: General Introduction	1-13
1.1 Introduction	1
1.2 Problems associated with non-biodegradable food packaging	1
1.3 Bio-based polymers used in food packaging applications	2
1.3.1 Decomposition of bio-based polymers	2
1.4 Nano-composites	4
1.5 Nanofibers by electrospinning	4
1.6 Impact of bio-based biodegradable polymers	5
1.6.1 Food packaging	5
1.6.2 Biomedical and pharmaceutical applications of biodegradable polymers	5
1.6.2.1 Wound dressings	6
1.6.2.2 Nanoparticle-mediated drug delivery system	8
1.7 Research gap	9
1.8 Objectives	9
References	12
Chapter 2: Biodegradable antimicrobial polymeric nanocomposite films for packaging	15-83
2.1 Introduction	15
2.1.1 Bio-plastics	16
2.1.2 Food packaging	17

2.1.3	Foodborne pathogens	17
2.1.4	Antimicrobial packaging	18
2.1.4.1	Chitosan (CH) as antimicrobial packaging	19
2.1.4.2	Silver nanoparticles (AgNPs) as antimicrobial material	20
2.1.5	Electrospinning	22
2.1.6	Packaging of perishable meat products	22
2.2	Literature review	24
2.2.1	Biodegradation of plastic/polymer	25
2.2.2	Antimicrobial packaging	26
2.2.2.1	Polymeric antimicrobial composites of chitosan and their blends	28
2.2.2.2	Utilization of nanomaterials as antimicrobial agents in packaging	30
2.2.2.3	Silver nanoparticles (Ag-NPs)	31
2.2.2.4	Antimicrobial bio-nanocomposite films	34
2.2.3	Nanofibrous packaging	37
2.2.3.1	Electrospinning as a method of choice in packaging	39
2.2.4	Regulation for using nanomaterials in food packaging	43
2.3	Materials and methods	44
2.3.1	Materials	44
2.3.2	Collection & processing for preparation of <i>Ocimum tenuiflorum</i> leaf extract	44
2.3.3	Green Synthesis of silver nanoparticles (AgNPs) via plant extract and Chitosan (CH)	45
2.3.3.1	UV–Visible spectrophotometry	45
2.3.4	Electrospinning solution	46
2.3.4.1	Preparation of CH/PVA/AgNPs solution for electrospinning	46
2.3.4.2	Preparation of fibrous composite nano-layers (FCNLs) through electrospinning	46
2.3.5	Preparation of composite polymeric film	48
2.3.5.1	Diffusion of the active constituents	48
2.3.6	Physico-chemical characteristics	48
2.3.6.1	Electrical conductivity	48
2.3.6.2	Viscosity	48
2.3.6.3	Thickness	49

2.3.6.4	Solubility	49
2.3.6.5	Scanning electron microscopy (SEM)	49
2.3.6.6	Zeta (ζ) potential and particle size distribution	50
2.3.7	Water contact angle (WCA)	50
2.3.8	Fourier transforms infrared (FTIR) spectroscopy	50
2.3.9	X-ray diffraction (XRD)	51
2.3.10	Microbial Analysis	51
2.3.10.1	Culture media and microorganisms	51
2.3.10.2	<i>In vitro</i> antimicrobial activity	52
2.3.11	Antimicrobial application of FCNLs for meat packaging	52
2.3.12	Raw materials	53
2.3.12.1	Chitosan	53
2.3.12.2	Polyvinyl alcohol	54
2.4	Results and discussion	54
2.4.1	Analysis of UV–Visible spectra	54
2.4.2	Solution casting of polymeric film	57
2.4.2.1	The release profile of active constituents	58
2.5	Physico-chemical characteristics of electrospinning solution	59
2.5.1.1	Electrical conductivity	59
2.5.1.2	Viscosity	60
2.5.1.3	Thickness	61
2.5.1.4	Solubility	61
2.5.1.5	The SEM fingerprints	61
2.5.1.6	Zeta (ζ) potential of plant extract-AgNPs	65
2.5.2	Water contact angle (WCA)	66
2.5.3	Fourier Transform Infrared (FTIR) spectroscopy	67
2.5.4	X-ray diffraction (XRD)	68
2.5.5	Microbiological analysis	69
2.5.5.1	<i>In vitro</i> antimicrobial activity of film and FCNLs	69
2.5.6	Antimicrobial application of FCNLs for meat packaging	71
2.6	Conclusion	73
	References	75

Chapter 3: Nano-fibrous scaffold with curcumin for anti-scar wound healing 85-147

3.1	Introduction	85
3.2	Literature review	89
3.2.1	Wound care	89
3.2.2	Skin	90
3.2.2.1	Layers of skin	90
3.2.3	Wound	93
3.2.3.1	Types of wounds	93
3.2.3.1.1	Acute wound	93
3.2.3.1.2	Chronic wound	93
3.2.3.2	Types of clinical wound healing	94
3.2.3.2.1	Primary intention wound healing process	94
3.2.3.2.2	Secondary intention wound healing process	95
3.2.3.2.3	Tertiary intention wound healing process	95
3.2.4	Wound healing mechanism	95
3.2.4.1	Hemostasis	97
3.2.4.2	The inflammatory phase	98
3.2.4.3	Proliferative phase	98
3.2.4.4	Maturation or remodeling phase	98
3.2.5	Wound dressings	99
3.2.5.1	Types of wound dressing	100
3.2.6	Components of advanced wound dressings	104
3.2.6.1	Polyvinyl pyrrolidone (PVP)	104
3.2.6.2	Cerium nitrate	104
3.2.6.3	Curcumin as a bioactive agent	105
3.2.6.3.1	Safety	105
3.2.6.3.2	Bioavailability	106
3.2.6.3.3	Application of curcumin	108
3.2.6.3.4	Wound healing action mechanisms of curcumin	108

3.2.6.3.5	Recent studies on curcumin application in wound healing	110
3.3	Materials and methods	111
3.3.1	Materials	111
3.3.2	Preparation of solution for electrospinning of curcumin and cerium loaded nanofibers fabrication	112
3.3.3	Physicochemical characterisation of nanofibers	114
3.3.3.1	Thickness	114
3.3.3.2	Solubility	114
3.3.3.3	Scanning electron microscopy (SEM) of nanofibers	114
3.3.3.4	Fourier Transforms Infrared (FTIR) Spectroscopy	114
3.3.3.5	X-ray diffraction (XRD)	115
3.3.4	Water contact angle (WCA)	115
3.3.5	Nanofiber characteristics	115
3.3.5.1	<i>In vitro</i> free-radical scavenging efficacy of nanofibrous scaffolds	115
3.3.5.2	<i>In vitro</i> antimicrobial activity	116
3.3.6	Evaluation of the biocompatibility of the fibrous scaffolds	117
3.3.6.1	<i>In vitro</i> hemocompatibility assessment	117
3.3.6.2	Cytocompatibility assay (MTT assay)	117
3.3.7	<i>In vivo</i> open-wound healing	119
3.3.8	Histological examination	120
3.3.8.1	Histological examination of granulation tissues	120
3.3.8.2	Anti-oxidant enzyme activity in granulation tissues	120
3.3.8.2.1	Superoxide dismutase (SOD) assay	120
3.3.8.2.2	Catalase assay	121
3.3.8.3	Hydroxyproline content in granulation tissues	122
3.3.8.3.1	Standard curve for hydroxyproline	123
3.3.9	Statistical analysis	124
3.4	Results and discussion	125
3.4.1	Diameter and surface morphology of nanofibers	125
3.4.2	Physicochemical characteristics of nanofibers	127
3.4.3	Water contact angle (WCA)	129
3.4.4	<i>In vitro</i> free-radical scavenging efficacy of nano-fibrous scaffolds	130

3.4.5	<i>In vitro</i> antimicrobial activity	131
3.4.6	Biocompatibility evaluation of the fibrous scaffolds	131
3.4.6.1	<i>In vitro</i> hemocompatibility assessment	131
3.4.6.2	Cytocompatibility assay (MTT assay)	133
3.4.7	Results of <i>in vivo</i> open-wound healing study	133
3.4.8	Histological examinations of granulation tissues	136
3.4.8.1	Anti-oxidant enzyme activity in granulation tissues	137
3.4.8.2	Hydroxyproline content in granulation tissues	140
3.5	Conclusion	141
	References	142

Chapter 4: Nanoparticle-mediated drug delivery for biofilm-associated infections 149-184

4.1	Introduction	149
4.1.1	Biofilm over wounds	149
4.1.2	Biofilm-associated nosocomial infections	150
4.1.3	Strategies for biofilm eradication	150
4.1.4	Externally implanted devices (EIDs)	150
4.1.5	Nanoparticle-mediated drug delivery	152
4.2	Literature review	153
4.2.1	Strategies for biofilm eradication	157
4.2.2	Nanoparticle-based drug delivery systems	160
4.3	Materials and methods	162
4.3.1	Materials and reagents	162
4.3.2	Biofilm formation and quantification	162
4.3.3	Scanning electron microscopy (SEM)	163
4.3.4	Water contact angle (WCA)	163
4.3.5	Preparation of Eudragit-RL100 nanoparticle encapsulated gentamicin sulfate (E-G-S)	164
4.3.5.1	Drug entrapment efficiency	164
4.3.5.2	<i>In vitro</i> gentamicin sulfate release kinetic study	165
4.3.5.3	Standard curve for gentamicin sulfate (G-S)	165

4.3.6	Antimicrobial assessment	166
4.3.7	Determination of minimum inhibitory concentration (MIC) of gentamicin sulfate (G-S)	166
4.3.8	Determination of minimum biofilm inhibitory concentration (MBIC) of G-S and E-G-S	167
4.4	Results and discussion	167
4.4.1	Biofilm formation and quantification	167
4.4.2	Physical characteristic of EIDs by SEM	169
4.4.3	Water contact angle (WCA)	171
4.4.4	Physical characteristic of Eudragit-RL100 nanoparticle encapsulated gentamicin sulfate (E-G-S)	172
4.4.4.1	Drug entrapment efficiency	173
4.4.4.2	<i>In vitro</i> G-S release kinetics	173
4.4.5	Minimum inhibitory concentration (MIC) of G-S	174
4.4.6	Minimum biofilm inhibitory concentration (MBIC) of G-S	175
4.4.7	MBIC of Eudragit RL100 nanoparticle-encapsulated G-S (E-G-S)	176
4.5	Conclusion	178
	References	180
Chapter 5: Conclusions and future aspects		185-189
5.1	Conclusion	185
5.2	Future aspects	188
List of Publications		190
